Camostat mesylate, a TMPRSS2 inhibitor authorized for treating pancreatitis, has been confirmed to inhibit TMPRSS2 activity and prevent the fusion of the SARS-CoV-2 virus with the host cell membrane [40]. This evidence concerns the gene TMPRSS2 and pancreatitis.